BioInvent cuts another 20 staff 'to focus only on cancer'
This article was originally published in Scrip
Executive Summary
BioInvent International is narrowing its focus further by concentrating on developing new antibody drugs for only cancer indications. The latest strategy change will result in 20 people losing their jobs.